FindTrial
Sign In

Volume replacement with diced acellular dermal matrix in oncoplastic breast conserving surgery

Clinical efficacy of Megaderm for breast cancer patients receiving conservation

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0003886
Enrollment
120
Registered
2019-05-03
Start date
2017-12-15
Completion date
Unknown
Last updated
2019-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

The Catholic University of Korea, St. Vincent's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Women under 20 years of age and under 80 years of age who were diagnosed with breast cancer and selected conservative surgery. Patients who are allowed to use the Megaderm and who can be followed up for more than 2 months after surgery.

Exclusion criteria

Exclusion criteria: Patients with infectious diseases, autoimmune diseases, blood clotting disorders Patients with adverse reactions to primary antibiotics Patients with suspected inflammatory infections before the operation pregnant woman Patients who were judged by the clinical trial leader to be difficult to collect.

Design outcomes

Primary

MeasureTime frame
cosmetic satisfaction—

Secondary

MeasureTime frame
surgical complication—

Countries

Korea, Republic of

Contacts

Public ContactHongki Gwak

The Catholic University of Korea, St. Vincent's Hospital

ghosthki@naver.com+82-31-249-8986

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 18, 2026